<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab4">
 <label>Table 4</label>
 <caption>
  <p>Antiviral treatment</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Antiviral agents and age group [
     <xref ref-type="bibr" rid="CR64">64</xref>]
    </th>
    <th>Treatment dosing</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="2">Oseltamivir</td>
   </tr>
   <tr>
    <td> Adults (including pregnancy)</td>
    <td>75 mg twice daily</td>
   </tr>
   <tr>
    <td> Children (1 year or older) ≤15 kg</td>
    <td>30 mg twice daily</td>
   </tr>
   <tr>
    <td> Children &gt; 15–23 kg</td>
    <td>45 mg twice daily</td>
   </tr>
   <tr>
    <td> Children &gt; 23–40 kg</td>
    <td>60 mg twice daily</td>
   </tr>
   <tr>
    <td> Children &gt; 40 kg</td>
    <td>75 mg twice daily</td>
   </tr>
   <tr>
    <td> Term Infants 0–11 months*</td>
    <td>
     <italic>See details in footnote</italic>
    </td>
   </tr>
   <tr>
    <td> Preterm infants**</td>
    <td>
     <italic>See details in footnote</italic>
    </td>
   </tr>
   <tr>
    <td colspan="2">Zanamivir</td>
   </tr>
   <tr>
    <td> Adults</td>
    <td>10 mg (two 5-mg inhalations), twice daily</td>
   </tr>
   <tr>
    <td> Children (≥ 7 years)</td>
    <td>10 mg (two 5-mg inhalations), twice daily</td>
   </tr>
   <tr>
    <td colspan="2">Peramivir</td>
   </tr>
   <tr>
    <td> Adults</td>
    <td>600 mg intravenous infusion once, given over 15–30 min</td>
   </tr>
   <tr>
    <td> Children (2–12 years)</td>
    <td>One 12 mg/kg dose, up to 600 mg maximum, intravenous, given over 15–30 min</td>
   </tr>
   <tr>
    <td> Children (13–17 years)</td>
    <td>600 mg intravenous infusion once, given over 15–30 min</td>
   </tr>
   <tr>
    <td colspan="2">Baloxavir marboxil***</td>
   </tr>
   <tr>
    <td> Adults and children (12 years or older) ≥40–80 kg</td>
    <td>Single dose of 40 mg</td>
   </tr>
   <tr>
    <td> Adults and children (12 years or older) ≥80 kg</td>
    <td>Single dose of 80 mg</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>*FDA-approved oral oseltamivir treatment dose for infants 14 days and older and less than 1 year old is 3 mg/kg per dose twice daily. The American Academy of Pediatrics has recommended an oseltamivir treatment dose of 3.5 mg/kg orally twice daily for infants 9–11 months of age</p>
  <p>**Current weight-based dosing recommendations are not appropriate for premature infants. Please refer to American Academy of Pediatrics recommendations (
   <ext-link ext-link-type="uri" xlink:href="https://pediatrics.aappublications.org/content/142/4/e20182367" xmlns:xlink="http://www.w3.org/1999/xlink">https://pediatrics.aappublications.org/content/142/4/e20182367</ext-link>) for further information
  </p>
  <p>***Safety and efficacy of baloxavir marboxil in patients less than 12 years old or weighing less than 40 kg have not been established. There are no data on balosavir treatment of hospitalized patients with influenza, and appropriate dosing frequency is unknown. A phase III clinical trial of baloxavir treatment of hospitalized influenza patients is ongoing: 
   <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03684044" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT03684044</ext-link>
  </p>
 </table-wrap-foot>
</table-wrap>
